Arcturus Therapeutics Holdings Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 45.14 million compared to USD 13.37 million a year ago. Net loss was USD 16.22 million compared to USD 35.27 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 1.33 a year ago. Diluted loss per share from continuing operations was USD 0.61 compared to USD 1.33 a year ago.
For the nine months, revenue was USD 135.94 million compared to USD 45.71 million a year ago. Net loss was USD 18.02 million compared to USD 108 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 4.09 a year ago. Diluted loss per share from continuing operations was USD 0.68 compared to USD 4.09 a year ago.